Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
* Adjunctive treatment of seizures in patients 2 years of age and older with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** Start at 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week as tolerated, not to exceed the maximum daily dose.
* **Maintenance:** Typical maintenance dose is 10 mg to 20 mg twice daily.
* **Maximum Daily Dose:** 20 mg twice daily (40 mg/day) for patients weighing less than 30 kg, and 40 mg twice daily (80 mg/day) for patients weighing 30 kg or more.
## Pediatric Dosing
* **Patients 2 to <10 years of age OR weighing <30 kg:**
* **Initiation:** Start at 2.5 mg twice daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week as tolerated.
* **Maximum Daily Dose:** 10 mg twice daily (20 mg/day).
* **Patients 10 years of age and older OR weighing ≥30 kg:**
* **Initiation:** Start at 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week as tolerated.
* **Maximum Daily Dose:** 20 mg twice daily (40 mg/day).
*Note: Dosing should be individualized based on response and tolerance. The target maintenance dose for LGS is generally 0.5-1 mg/kg/day, divided into two doses, not to exceed the maximum daily doses listed above.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are established, but consider lower starting doses and slower titration.
* **Renal Impairment:** Use with caution. No specific dose adjustment guidelines are established, but consider lower starting doses and slower titration.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, fatigue, drooling, constipation, decreased appetite, aggression, irritability, respiratory infections, vomiting.
* **Serious:** Severe dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms (especially with abrupt discontinuation), suicidal behavior or ideation, paradoxical reactions, respiratory depression.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression; increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam levels, increasing risk of adverse effects.
* **CYP3A4 Inducers (e.g., carbamazepine, rifampin):** May decrease clobazam levels, potentially reducing efficacy.
* **CNS Stimulants:** May antagonize the sedative effects of clobazam.
## Monitoring
* Monitor for signs of somnolence, sedation, and fatigue, especially at the beginning of therapy or with dose increases.
* Assess for behavioral changes, including aggression, irritability, and suicidal ideation.
* Monitor for signs of withdrawal if discontinuing therapy.
* Evaluate seizure frequency and severity.
## Clinical Pearls
* Clobazam is typically used as add-on therapy. Do not use as monotherapy for absence or myoclonic seizures.
* Gradual withdrawal is recommended to avoid potential withdrawal symptoms.
* Due to the risk of serious skin reactions, patients should be advised to discontinue clobazam and seek immediate medical attention if they develop a rash.
* Clobazam is a Schedule IV controlled substance.
---
**Disclaimer:** This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and relevant guidelines. Always verify current drug information before making clinical decisions.
